Condensed Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows from operating activities:
Net income (loss)	$ 846,100	$ (5,896,839)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	65,578	77,682
Amortization	16,692	7,171
Change in fair value of conversion option liability	(1,513,413)	0
Change in fair value of warrants liabilities	(3,683,000)	0
Amortization of right-of-use assets	118,180	132,207
Loss on fixed asset dispositions	0	43,507
Share-based compensation expense	151,608	367,237
Amortization of debt issuance costs and discount	176,607	356,699
Changes in operating assets and liabilities:
Accounts receivable	444,336	254,775
Inventory	(365,018)	(815,865)
Prepaid and other assets	168,722	(53,523)
Accounts payable	(253,439)	890,678
Accrued expenses	(193,226)	19,239
Lease liabilities	(125,280)	(133,076)
Other liabilities	2,045	(15,106)
Net cash used in operating activities	(4,143,508)	(4,765,214)
Cash flows from investing activities:
Purchases of property and equipment	(79,138)	(96,605)
Net cash used in investing activities	(79,138)	(96,605)
Cash flows from financing activities:
Proceeds from at-the-market sales of common stock	352,922	5,392,027
Issuance costs for at-the-market sales of common stock	(10,588)	(161,761)
Net cash provided by financing activities	342,334	5,230,266
Net change in cash and cash equivalents	(3,880,312)	368,447
Cash and cash equivalents:
Beginning of period	9,266,353	3,451,761
End of period	5,386,041	3,820,208
Cash paid for:
Interest	0	0
Taxes	0	0
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable	14,876	22,072
Acquisition of patents included in accounts payable	6,030	0
Conversion of November 2025 convertible notes into common stock	76,452	0
Payment of November 2023 convertible note interest in common stock	47,841	0
Deferred offering costs reclassified to additional paid-in-capital	$ 174	$ 8,369